Effects of immune system cells in GvHD and corresponding therapeutic strategies.

IF 2.3 Q2 HEMATOLOGY Blood Research Pub Date : 2023-03-31 DOI:10.5045/br.2023.2022192
Maryam Jadid Tavaf, Mahboobeh Ebrahimi Verkiani, Fateme Poorhoseini Hanzaii, Mina Soufi Zomorrod
{"title":"Effects of immune system cells in GvHD and corresponding therapeutic strategies.","authors":"Maryam Jadid Tavaf,&nbsp;Mahboobeh Ebrahimi Verkiani,&nbsp;Fateme Poorhoseini Hanzaii,&nbsp;Mina Soufi Zomorrod","doi":"10.5045/br.2023.2022192","DOIUrl":null,"url":null,"abstract":"<p><p>Allogeneic tissue transplantation is one of the most effective treatments for several diseases and injuries, in particular, malignant and non-malignant hematological conditions. Following this procedure, transplanted tissue encounters various complications, one of the most serious being graft-versus-host disease (GvHD). The management of GvHD directly affects the success of transplantation and the survival rate of the patient; therefore, many studies have focused on GvHD prevention and control. This review briefly explains the transplantation process, causes of graft rejection, and importance of the human leukocyte antigen system. Initially, we address the pathophysiology and immunobiology of GvHD, the cells involved in this complication, the differences between chronic and acute GvHD, and the importance of graft-versus-leukemia. Interestingly, various types of immune cells are involved in GvHD pathogenesis. After explaining how these cells affect the GvHD process, we discuss the studies conducted to control and reduce GvHD symptoms.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 1","pages":"2-12"},"PeriodicalIF":2.3000,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/11/1f/br-58-1-2.PMC10063589.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2022192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Allogeneic tissue transplantation is one of the most effective treatments for several diseases and injuries, in particular, malignant and non-malignant hematological conditions. Following this procedure, transplanted tissue encounters various complications, one of the most serious being graft-versus-host disease (GvHD). The management of GvHD directly affects the success of transplantation and the survival rate of the patient; therefore, many studies have focused on GvHD prevention and control. This review briefly explains the transplantation process, causes of graft rejection, and importance of the human leukocyte antigen system. Initially, we address the pathophysiology and immunobiology of GvHD, the cells involved in this complication, the differences between chronic and acute GvHD, and the importance of graft-versus-leukemia. Interestingly, various types of immune cells are involved in GvHD pathogenesis. After explaining how these cells affect the GvHD process, we discuss the studies conducted to control and reduce GvHD symptoms.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
免疫系统细胞在GvHD中的作用及其治疗策略。
同种异体组织移植是治疗多种疾病和损伤,特别是恶性和非恶性血液病最有效的方法之一。在此过程中,移植组织会遇到各种并发症,其中最严重的是移植物抗宿主病(GvHD)。GvHD的处理直接影响移植的成功和患者的生存率;因此,GvHD的预防和控制成为许多研究的重点。本文简要介绍了移植过程、移植排斥反应的原因以及人白细胞抗原系统的重要性。首先,我们讨论了GvHD的病理生理学和免疫生物学,参与这种并发症的细胞,慢性和急性GvHD之间的差异,以及移植物抗白血病的重要性。有趣的是,多种类型的免疫细胞参与了GvHD的发病机制。在解释了这些细胞如何影响GvHD过程之后,我们讨论了控制和减少GvHD症状的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood Research
Blood Research HEMATOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
64
期刊最新文献
Correction: Hepatitis B surface antigen reverse seroconversion after hematopoietic stem cell transplantation according to the baseline serological marker levels and vaccination status: a single‑center database analysis. Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Back to basics: the coagulation pathway. Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1